Publications

Is CD37-targeted therapy a viable alternative in the treatment of diffuse large B-cell lymphoma? Interviews with two key opinion leaders

Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell…